DAAN Biotherapeutics, a South Korea-based biotech company, has entered into a licensing agreement with GC Cell to advance cell therapies targeting solid tumors. The deal grants GC Cell exclusive rights to use DAAN’s antibody sequence in developing CAR-T and CAR-NK cell therapies. This antibody targets a tumor-associated antigen found in several major solid cancers, including colorectal and lung cancer, and is expected to enhance the specificity and effectiveness of cell-based immunotherapies.
By integrating DAAN’s antibody with GC Cell’s CAR cell-therapy platform, the partnership aims to improve treatment efficacy while minimizing side effects, providing a next-generation alternative to current cancer therapies. The agreement includes upfront and milestone payments, plus royalties on future product sales, though specific financial terms remain confidential.
DAAN’s CEO, Byoung-Chul Cho, emphasized the company’s continued commitment to advancing cancer therapeutics. This deal follows DAAN’s February 2025 agreement with LigaChem Biosciences for antibody-drug conjugate (ADC) development, further showcasing DAAN’s growing influence in target discovery and antibody engineering.
Together, DAAN and GC Cell aim to commercialize innovative cell therapies that could transform outcomes for patients with hard-to-treat solid tumors, advancing the broader field of cell and gene therapy.
Source:
https://www.pharmaceutical-technology.com/news/daan-gc-cell/
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
